Predictors of uncommon location of sentinel nodes in endometrial and cervical cancers.


Journal

Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 30 10 2021
revised: 17 12 2021
accepted: 21 12 2021
entrez: 13 1 2022
pubmed: 14 1 2022
medline: 14 1 2022
Statut: epublish

Résumé

Sentinel node mapping is widely used in the treatment of gynecologic cancers. The current study aimed to identify predictors of uncommon sentinel lymph node (SLN) locations. The current study included women who were operated for endometrial or cervical cancer with attempted sentinel lymph node mapping during surgical staging. Data were collected from electronic charts. The pelvis and the external ilia and obturator basins were common node locations. Para-aortic, pre-sacral, common iliac, internal iliac, and parametrial nodes were considered uncommon locations. We conducted analyses stratified according to common, uncommon, and very uncommon ( A total of 304 women were enrolled in the current study; 15.8% had SLN in uncommon locations and 4.3% had very uncommon node locations. Body mass index (BMI) was a negative predictor for uncommon SLN locations (OR 0.88, p = 0.03). The use of either indocyanine green (ICG) or Tc BMI, tracer type, surgical year, and positive nodes were independent predictors for uncommon SLN locations. These findings suggest that surgical effort, technique and experience may result in better identification of uncommon SLN locations.

Identifiants

pubmed: 35024403
doi: 10.1016/j.gore.2021.100917
pii: S2352-5789(21)00221-6
pmc: PMC8724951
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100917

Informations de copyright

© 2022 The Authors. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Gynecol Oncol. 2017 Oct;147(1):18-23
pubmed: 28716308
Int J Gynecol Cancer. 2017 Jan;27(1):154-158
pubmed: 27792042
Gynecol Oncol. 2010 Jan;116(1):28-32
pubmed: 19875161
Gynecol Oncol. 2006 Oct;103(1):35-44
pubmed: 16600355
Eur J Surg Oncol. 2015 Jan;41(1):1-20
pubmed: 25454828
Lancet Oncol. 2017 Mar;18(3):384-392
pubmed: 28159465
Gynecol Oncol. 2019 Jul;154(1):102-109
pubmed: 31003746

Auteurs

Yfat Kadan (Y)

Gynecologic Oncology Division, Department of Obstetrics and Gynecology, HaEmek Medical Center, affiliated with Technion Institute of Technology, Haifa, Israel.

Alexandra Baron (A)

Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Meir Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Yoav Brezinov (Y)

Department of Obstetrics and Gynecology, Kaplan Medical Center, Rehovot, Affiliated to the Hebrew University, Medical School, Jerusalem, Israel.

Alon Ben Arie (A)

Department of Obstetrics and Gynecology, Kaplan Medical Center, Rehovot, Affiliated to the Hebrew University, Medical School, Jerusalem, Israel.

Ami Fishman (A)

Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Meir Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Mario Beiner (M)

Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Meir Medical Center, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Classifications MeSH